Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Carcinoma, Anaplastic 4Neuroendocrine Tumors 4Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Adenocarcinoma, Follicular 2Wilms Tumor 1Vipoma 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Somatostatinoma 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Insulinoma 1Glucagonoma 1Gastrinoma 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1

Interventions

Everolimus 5Octreotide 4Leucovorin 3Capecitabine 3vatalanib 2Trastuzumab 2Temozolomide 2Oxaliplatin 2Melphalan 2Fluorouracil 2Biological Therapy 2Bevacizumab 2tipifarnib 1temsirolimus 1romidepsin 1regorafenib 1pentetreotide 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Irinotecan 1Interleukin-12 Subunit p35 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × Sorafenib × Endocrine × Clear all
NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡